摘要
目的观察人参皂甙Rg3对大鼠子宫内膜异位症(EMs)组织中微血管密度(MVD)影响和抗血管生成作用。方法参照Jones方法[1]建立Wistar大鼠EMs动物模型,3周后将建模成功的大鼠随机分为空白对照、孕三烯酮和人参皂甙Rg3各2、4、6及8周组共12组,通过CD31标记异位子宫内膜血管,用SABC免疫组化法测定异位灶组织中MVD的表达。结果Rg3治疗大鼠EMs模型2、4、6、8周后,异位组织中MVD数量明显低于对照组(P<0.05),而孕三烯酮治疗相同时间后与对照组相比,MVD数量无明显改变(P>0.05),Rg3并且随治疗时间延长,MVD数量明显减少(P<0.05),而正常对照组和孕三烯酮组无此表现。结论Rg3对大鼠EMs组织中MVD表达和新生血管生成均有抑制作用,Rg3有望成为EMs抗血管生成治疗新药。
Objective To observe the effect of ginsenoside Rg3 on micro -vessel density （MVD） of endometriosis in vivo. Methods Endometriosis models of Wistar rats were established referring to Jones methods. The endometriosis rats were treated with either ginsenoside Rg3 or gestrinone, compared with untreated rats. MVD was immunohistochemically determined （SABC technique） at 2, 4, 6 and 8 weeks of treatment, respectively. Results Compared to the untreated rats, MVD in endometriosis were decreased remarkably after ginsenoside Rg3 treating for 2 , 4 , 6 or 8 weeks （ P 〈 0. 0 5 ） . However , significant difference was not observed in rats treated with gestrinone （P〉0.05）. Furthermore, the decrease was more remarkable when treated longer with ginsenoside Rg3 （P〈0.05）. Conclusions Ginsenoside Rg3 suppresses antiangiogenesis in endometriosis tissue in vivo. Ginsenoside Rg3 may be a potential drug for treating endometriosis.
出处
《中国妇产科临床杂志》
2006年第5期348-350,371,共4页
Chinese Journal of Clinical Obstetrics and Gynecology
基金
山西省卫生厅基金项目(200417)资助
